Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy

Urologia Internationalis

Volumn 87, Issue 3, 2011, Pages 270-275

  Castillejos Molina, Ricardo ^a   Rodríguez Covarrubias, Francisco ^a   Sotomayor, Mariano ^a   Gómez Alvarado, M Olivia ^a   Villalobos Gollás, Miguel ^a   Gabilondo, Fernando ^a   Feria Bernal, Guillermo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Metabolic syndrome; Prognostic factors; Prostate cancer; Radical prostatectomy

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; GLEASON SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURVIVAL TIME;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80055046590     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000329280     Document Type: Article

References (44)

1. Hsing AW, Devesa SS: Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 2001; 23: 3-13.
2. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60-67.
3. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
4. Boyle P, Severi G, Giles G: The epidemiology of prostate cancer. Urol Clin North Am 2003; 30: 209-217.
5. Boyle P, Ferlay J: Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16: 481-488.
6. Registro Histopatológico de Neoplasias Malignas. Compendio Mortalidad y Morbilidad SSA, México 2003.
7. Ward JF, Blute ML, Slezak J, et al: The longterm clinical impact of biochemical recurrence of prostate cancer five or more years after radical prostatectomy. J Urol 2003; 170: 1872-1876.
8. Zhou JR, Blackburn GL, Walker A: Symposium introduction: Metabolic syndrome and the onset of cancer. Am J Clin Nutr 2007; 86 (suppl):817S-819S.
9. Reaven GM: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
10. Pi-Sunyer X: The metabolic syndrome: How to approach differing definitions. Med Clin North Am 2007; 91: 1025-1040.
11. Glode ML: Metabolic syndrome and prostate cancer. Cancer 2008; 112: 2103-2105.
12. Grundmark B, Garmo H, Loda M, et al: The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010; 19:2088-2096.
13. Hsing AW, Sakoda LC, Chua SC: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86 (suppl):843S-857S.
14. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-2449.
15. Sarma AV, Wallner LP, Daignault S, et al: Metabolic syndrome and risk of prostate cancer: NHANES 2001-2002. Atlanta, AUA, 2006, abstr 126.
16. Coman I, Crisan N, Marian A, et al: Prevalence of the metabolic syndrome in patients with prostate cancer. J Gastrointest Liver Dis 2008; 17: 237-238.
17. Hammarsten J, Högstedt B: Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47-55.
18. Giovannucci E, Michaud D: The role of obesity and related metabolic syndrome disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-2225.
19. Hammarsten J, Högstedt B: Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895.
20. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
21. Blaha MJ, Bansal S, Rouf R, et al: A practical 'ABCDE' approach to the metabolic syndrome. Mayo Clin Proc 2008; 83: 932-943.
22. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate-specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001; 165: 1146-1151.
23. Stephenson AJ, Kattan MW, Eastham JA, et al: Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardization definition. J Clin Oncol 2006; 24: 3973-3978.
24. Carroll P, Albertsen PC, Greene K, et al: Prostate-specific antigen best practice statement: 2009 update (http://www.auanet.org/ content/guidelines-and- quality-care/clinical-guidelines/main-reports/psa09.pdf).
25. Spark RF: Testosterone, diabetes mellitus and the metabolic syndrome. Curr Urol Rep 2007; 8: 467-471.
26. Dandona P, Aljada A, Chaudhuri A, et al: Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
27. Ma J, Li H, Giovannucci E, et al: Prediagnostic body mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men wit prostate cancer: A longterm survival analysis. Lancet Oncol 2008; 9: 1039-1047.
28. Freedland SJ, Terris MK, Platz EA, et al: Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 2005; 66: 108-113.
29. Freedland SJ, Banez LL, Sun LL, et al: Obese men have higher-grade and larger tumors: An analysis of the Duke Prostate Center database. Prostate Cancer Prostatic Dis 2009; 12: 259-263.
30. Gong Z, Agalliu I, Lin DW, et al: Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202.
31. Baillargeon J, Rose DP: Obesity, adipokines, and prostate cancer. Int J Oncol 2006; 28: 737-745.
32. O'Malley RL, Taneja SS: Obesity and prostate cancer. Can J Urol 2006; 13(suppl 2):11-17.
33. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2000; 11: 327-332.
34. Bulcao C, Ferreira SR, Giuffrida FM, et al: The new adipose tissue and adipocytokines. Curr Diabetes Rev 2006; 2: 19-28.
35. Andersson SO, Wolk A, Belgström R, et al: Body size and prostate cancer: A 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-389.
36. Kong AP, Chan NN, Chan JC: The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev 2006; 2: 397-407.
37. Rodriguez C, Freedland SJ, Deka A, et al: Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-69.
38. Barnard RJ: Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr 2007; 86(suppl):889S-893S.
39. Beebe-Dimmer JL, Dunn RL, Sarma AV, et al: Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881.
40. Laukkanen JA, Laaksonen DE, Niskanen L, et al: Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
41. Lund Haheim L, Wisloff TF, Holme I, et al: Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.
42. Martin RM, Vatten L, Gunnel D, et al: Components of the metabolic syndrome and risk of prostate cancer: The HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181-1192.
43. Stocks T, Lukanova A, Rinaldi S, et al: Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. Int J Cancer 2007; 120: 2678-2686.
44. Tande AJ, Platz EA, Folsom AR: The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102.